Stories

What is inside a nicotine pouch matters because consumers deserve to understand the products they use. Beyond nicotine, pouches typically contain plant-based fibres, pH adjusters, flavourings, sweeteners and stabilisers that affect how the product feels, tastes and delivers nicotine. That does not make them risk-free, but it does make them very different from cigarettes, where burning tobacco creates thousands of toxic chemicals. Better public health communication should explain product contents clearly, rather than leaving nicotine pouches to be judged by suspicion alone.

The Royal College of Physicians has historically helped move the UK debate towards harm reduction, which makes any drift back into risk confusion especially significant. Clinical leadership should make the hierarchy clear: smoking remains the central danger, while smoke-free nicotine products can offer adults a less harmful route away from combustion. Overstating uncertainty or treating alternatives too cautiously may leave smokers with the impression that switching offers little benefit. Medical authority should reduce confusion, not reinforce the conditions that keep cigarettes in use.

Estonia’s smoking rate falling by more than a quarter while vaping more than triples is a trend policymakers should examine closely. It suggests a shift in nicotine use that may be moving some adults away from combustible tobacco rather than simply adding new use. The important question is not whether vaping increased in isolation, but what happened to smoking at the same time. Regulation should protect young people and maintain product standards, while recognising that movement away from cigarettes can be a meaningful public health gain.

The EU’s direction on nicotine bans should be judged by what it leaves behind. Removing smoke-free alternatives from legal markets does not remove nicotine use; it can leave adult smokers with fewer routes away from cigarettes and give illicit suppliers more room to grow. That is the risk of policy built around exclusion rather than comparison. A European tobacco strategy should distinguish between products, protect young people through enforcement, and keep lower-risk options available for those still exposed to combustion.

The FDA’s tobacco centre reworking its product review process matters because the current system has struggled to keep pace with the market it is supposed to regulate. Slow, uncertain pathways can leave responsible products waiting while cigarettes remain widely available and unapproved alternatives continue to circulate. A better review model should be faster without becoming weaker: clear standards, transparent decisions and evidence assessed according to relative risk. The goal should be a legal market where safer nicotine products are reviewed in time to help smokers move away from combustion.

The latest ONS figures show Britain’s smoking rate at another record low, with fewer than one in ten adults now smoking and the sharpest long-term fall among young adults. That is the context in which the Government’s tougher approach to vaping looks increasingly hard to justify. Restrictions on price, packaging and visibility may be designed to deter youth use, but they also risk weakening a tool that has helped many adults move away from cigarettes. Policy should protect young people without disrupting the progress already being made against smoking.

Queensland’s enforcement blitz shows that illicit tobacco markets can be disrupted when store closures, serious fines and landlord accountability are used together. The reported rise in legal tobacco sales and doubling of Quitline calls suggest that enforcement can move consumers back into visible channels and prompt interest in quitting. But the measure of success should not be tax-compliant cigarette sales alone. Australia should pair stronger action against illegal supply with expanded cessation support, free nicotine replacement therapy and access to lower-risk alternatives, so the end result is fewer people smoking — not just more people buying cigarettes legally.

“Safer” is not a loophole in public health; it is the point of harm reduction. For people who cannot or will not stop using nicotine immediately, the difference between burning tobacco and using a lower-risk product can be the difference between continued exposure and meaningful risk reduction. Demanding “safe” before accepting “safer” leaves cigarettes with an advantage they do not deserve. Public health should care about every step that moves people away from the most harmful option.

Public health loses authority when it treats disagreement as a threat rather than a test of its own claims. In nicotine policy, declaring one position beyond challenge can shut out evidence on relative risk, consumer behaviour and the unintended effects of restriction. Confidence is not the same as accountability. Institutions earn trust by showing their reasoning, correcting errors and allowing policy to be questioned when real-world outcomes do not match the promise.

One hundred and twenty thousand lived experiences should be difficult for policymakers to ignore. Behind the EU nicotine consultation are smokers, vapers, pouch users and people who have already changed their risk by moving away from cigarettes. Their evidence is not laboratory data, but it is evidence of how policy works in real life. Europe’s next nicotine framework should listen to those experiences before deciding which products adults are allowed to understand, access or use.